Sensorion Announces Approval of Shareholders’ Meeting Resolutions

On May 13, 2025, Sensorion, a biotechnology company focused on hearing loss therapies, reported the approval of all resolutions at its Combined General Meeting (CGM) held on May 12, 2025. The approval rate was significant, with 81.7% of the share capital present and represented. These resolutions were in line with board recommendations.

Interested parties can find detailed voting results on the Sensorion website, specifically in the Investors section under the Governance tab. This outcome supports Sensorion's ongoing development of innovative treatments for hearing loss, including gene therapy and small molecule research. The company's efforts are aimed at addressing both hereditary and acquired hearing disorders.